Aronex Atragen
Executive Summary
Injectable tretinoin liposome receives "non-approvable" letter because clinical trials did not establish an identifiable population of acute promyelocytic leukemia patients requiring a non-oral formulation, company says. Aronex needed to show efficacy in a population in which I.V. administration is required because of the orphan exclusivity of Roche's oral tretinoin Vesanoid. Aronex plans to study Atragen for non-Hodgkin's lymphoma in a Phase III 200-patient trial. The company will lay off most its 85 employees, retaining only clinical and regulatory personnel
You may also be interested in...
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Shire Hopes To Sow Future Deals With $50M Venture Fund
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth